AU2012235767B2 - Markers for identifying tumor cells, methods and kit thereof - Google Patents

Markers for identifying tumor cells, methods and kit thereof Download PDF

Info

Publication number
AU2012235767B2
AU2012235767B2 AU2012235767A AU2012235767A AU2012235767B2 AU 2012235767 B2 AU2012235767 B2 AU 2012235767B2 AU 2012235767 A AU2012235767 A AU 2012235767A AU 2012235767 A AU2012235767 A AU 2012235767A AU 2012235767 B2 AU2012235767 B2 AU 2012235767B2
Authority
AU
Australia
Prior art keywords
combination
cadherin
cells
biological markers
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012235767A
Other languages
English (en)
Other versions
AU2012235767A1 (en
Inventor
Manjiri Bakre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncostem Diagnostics (Mauritius) Pvt Ltd
Original Assignee
Oncostem Diagnostics (Mauritius) Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncostem Diagnostics (Mauritius) Pvt Ltd filed Critical Oncostem Diagnostics (Mauritius) Pvt Ltd
Publication of AU2012235767A1 publication Critical patent/AU2012235767A1/en
Application granted granted Critical
Publication of AU2012235767B2 publication Critical patent/AU2012235767B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
AU2012235767A 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof Active AU2012235767B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2835CH2010 2011-03-27
IN2835/CHE/2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (2)

Publication Number Publication Date
AU2012235767A1 AU2012235767A1 (en) 2013-11-07
AU2012235767B2 true AU2012235767B2 (en) 2016-02-04

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012235767A Active AU2012235767B2 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Country Status (8)

Country Link
US (2) US8772455B2 (https=)
EP (1) EP2691776A4 (https=)
JP (1) JP2014515821A (https=)
KR (1) KR101621036B1 (https=)
CN (1) CN103562723B (https=)
AU (1) AU2012235767B2 (https=)
SG (1) SG193630A1 (https=)
WO (1) WO2012131564A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938583B2 (en) 2013-03-15 2018-04-10 Varian Medical Systems, Inc. Biomarkers for radiation treatment
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
US10900968B2 (en) * 2016-05-24 2021-01-26 Oncostem Pte. Ltd. Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080601A2 (en) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
DE602005018789D1 (de) * 2004-08-10 2011-05-26 Cardiff Biolog Ltd Verfahren und kit zur prognose von brustkrebs
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
UA110315C2 (uk) * 2006-09-29 2015-12-25 Oncomed Pharm Inc Композиція та спосіб лікування раку
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
US7968169B2 (en) * 2007-08-07 2011-06-28 The Boeing Company Compound contoured composite beams and fabrication methods
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2011007853A1 (ja) * 2009-07-14 2011-01-20 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONETH, G. et al., Breast Cancer Research, 2008, vol. 10, R53 *
LIU, Q. et al., Chinese Medical Journal, 2009, vol. 122, pages 2763-2769 *

Also Published As

Publication number Publication date
US8772455B2 (en) 2014-07-08
WO2012131564A1 (en) 2012-10-04
EP2691776A4 (en) 2015-04-15
CN103562723B (zh) 2017-04-26
CN103562723A (zh) 2014-02-05
EP2691776A1 (en) 2014-02-05
AU2012235767A1 (en) 2013-11-07
KR101621036B1 (ko) 2016-05-13
US20120244556A1 (en) 2012-09-27
KR20140015500A (ko) 2014-02-06
JP2014515821A (ja) 2014-07-03
US20140295459A1 (en) 2014-10-02
SG193630A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
AU2012235767B2 (en) Markers for identifying tumor cells, methods and kit thereof
Zhu et al. PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK
Park et al. Antibody-based detection of ERG rearrangement-positive prostate cancer
Rishi et al. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437
Cheng et al. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial–mesenchymal transition
US8470542B2 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
Lu et al. Increased expression of δ-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer
Qiu et al. Overexpression of CCT8 and its significance for tumor cell proliferation, migration and invasion in glioma
Cuevas et al. FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57
Lian et al. THAP11, a novel binding protein of PCBP1, negatively regulates CD44 alternative splicing and cell invasion in a human hepatoma cell line
Wang et al. Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation
Nie et al. TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer
Mao et al. CUL4B promotes bladder cancer metastasis and induces epithelial-to-mesenchymal transition by activating the Wnt/β-catenin signaling pathway
Qiu et al. RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis
Shao et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer
CN110302382A (zh) 一种靶向肿瘤细胞的药物
Heckler et al. Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer
Wang et al. Upregulation of ALDH1B1 promotes tumor progression in osteosarcoma
Lu et al. Elevation of EIF4G1 promotes non‐small cell lung cancer progression by activating mTOR signalling
Wang et al. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma
Deng et al. GID2 interacts with CDKN3 and regulates pancreatic cancer growth and apoptosis
Hwang et al. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma
Han et al. Expression of TRAP1 in gastric cancer tissue and its correlation with malignant biology
Zhao et al. The role of Alix in the proliferation of human glioma cells
Xu et al. Retracted: Suppression of BMX‐ARHGAP fusion gene inhibits epithelial‐mesenchymal transition in gastric cancer cells via RhoA‐mediated blockade of JAK/STAT axis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)